Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation (Q40106651)

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

17 September 2017

2 references

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation (English)

1 reference

17 September 2017

1 reference

4

Paul Dent

1 reference

17 September 2017

Girija Dasmahapatra

1

1 reference

17 September 2017

Nitin Yerram

series ordinal

2

1 reference

17 September 2017

Yun Dai

series ordinal

3

1 reference

17 September 2017

Steven Grant

series ordinal

5

1 reference

17 September 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

17 September 2017

Clinical Cancer Research

1 reference

17 September 2017

13

1 reference

17 September 2017

14

1 reference

17 September 2017

4280-4290

1 reference

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

17 September 2017

2 references

https://opencitations.net/index/api/v1/citations/10.1038/SJ.LEU.2403868

COCI

reference URL

30 December 2023

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide

2 references

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1124/MOL.105.017145

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Puma(*)Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

The biology of chronic myeloid leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Map kinase signaling pathways and hematologic malignancies

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

At the gates of death.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Acetylation and deacetylation of non-histone proteins

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1158/1078-0432.CCR-07-0835

Identifiers

DOI

10.1158/1078-0432.CCR-07-0835

1 reference

17 September 2017

1 reference